Heavenly Rx

SOL Global launches Heavenly Rx – a new international hemp-focused subsidiary

The company’s first investment will be in Bluhen Botanicals, purchasing a 50.1 percent stake for some US$30.6 million.
“We are launching Heavenly Rx with the aim of acquiring a portfolio of battle-tested and proven hemp/CBD companies while also acquiring certain unique brands for which we believe CBD and hemp-infused products could drastically change their growth,” added SOL’s chief investment officer Andy DeFrancesco. “We are more bullish than ever about the future of the hemp and CBD industries globally, and Heavenly Rx will without a doubt be the vertically integrated leader in the space. Heavenly Rx is not simply an investment company, but rather a laser-focused global Hemp and CBD company only for all operations under the Heavenly Rx banner.”